NUVATION BIO INC.

(NUVB)
  Report
Delayed Nyse  -  05/27 04:00:02 pm EDT
3.530 USD   +1.73%
05/11RBC Cuts Price Target on Nuvation Bio to $14 From $15, Maintains Outperform Rating, Speculative Risk Qualifier
MT
05/10Wedbush Adjusts Nuvation Bio Price Target to $17 From $23, Maintains Outperform Rating
MT
05/09Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Advance Premarket Thursday

01/20/2022 | 09:12am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ARGENX SE 2.25% 300.3 Real-time Quote.-4.76%
NASDAQ COMP. 3.33% 12131.13 Real-time Quote.-22.46%
NOVAVAX, INC. 17.46% 55.29 Delayed Quote.-61.35%
NUVATION BIO INC. 1.73% 3.53 Delayed Quote.-58.47%
All news about NUVATION BIO INC.
05/11RBC Cuts Price Target on Nuvation Bio to $14 From $15, Maintains Outperform Rating, Spe..
MT
05/10Wedbush Adjusts Nuvation Bio Price Target to $17 From $23, Maintains Outperform Rating
MT
05/09Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
BU
05/09Nuvation Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/04HC Wainwright Starts Nuvation Bio at Buy With $14 Price Target
MT
03/22BMO Capital Adjusts Nuvation Bio's Price Target to $12 From $17, Keeps Outperform Ratin..
MT
02/28NUVATION BIO : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Bu..
PU
02/28Nuvation Bio Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 20..
CI
02/28Nuvation Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/28Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides B..
BU
More news
Analyst Recommendations on NUVATION BIO INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -116 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,58x
Yield 2022 -
Capitalization 770 M 770 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 68
Free-Float 72,3%
Chart NUVATION BIO INC.
Duration : Period :
Nuvation Bio Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NUVATION BIO INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,53 $
Average target price 14,67 $
Spread / Average Target 315%
EPS Revisions
Managers and Directors
David T. Hung President, CEO & Director
Jennifer Fox Chief Financial Officer
Daniel G. Welch Chairman
Gary Hattersley Chief Scientific Officer
Robert B. Bazemore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NUVATION BIO INC.-58.47%770
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478